Skip to main content

Table 5 Novel HDACi combination therapies under investigation for relapsed/refractory peripheral T-cell lymphomas (Refer to Enrica Marchi et al.) [55]

From: Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma

Combination trials

Mechanism of action

Phase

ClinicalTrial.gov ID

Chidamide + CHOP

Anthracycline-containing regimens

I

NCT02809573

Chidamide + Cyclophosphamide + Thalidomide

HDAC inhibitor + Immunomodulatory drugs

II

NCT02879526

Romidepsin + CHOEP

Anthracycline-containing regimens

I/II

NCT02223208

Romidepsin + CHOP

Anthracycline-containing regimens

III

NCT01796002

Romidepsin + ICE

Anthracycline-containing regimens

I

NCT01590732

Romidepsin + Lenalidomide

HDAC inhibitor + Immunomodulatory drug

II

I/II

NCT02232516 NCT01742793

Belinostat + Carfilzomib

HDAC inhibitor + proteasome inhibitor

I

NCT02142530

Pralatrexate + Romidepsin

HDAC inhibitor + antifolate

I/II

NCT01947140

Romidepsin + 5-Azacitadine

hypomethylation agent + HDAC inhibitor

I/II

NCT01998035